Zentalis Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.48 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-12-31 was 343.20K shares.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.48M shares, a 71.09% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 8.60M shares, a 127.86% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.77M shares, a 29.21% decline from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 5.33M shares, a 248.92% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 2.48M shares 10-K · filed 2026-03-26 | |||
| 2024-12-31 | 8.60M shares 10-K · filed 2025-03-26 | |||
| 2023-12-31 | 3.77M shares 10-K · filed 2024-02-27 | |||
| 2022-12-31 | 5.33M shares 10-K · filed 2023-03-01 | |||
| 2021-12-31 | 1.53M shares 10-K · filed 2022-02-24 | |||
| 2020-12-31 | 343.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 3.14M shares 10-K · filed 2021-03-25 | ||
| 2020-09-30 | 2.79M shares 10-Q · filed 2020-11-09 | |||
| 2020-04-30 | 1.97M shares 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |